Astellas has a solid and proven track record in Urology, making it a Global Category Leader (GCL) in this field of medicine. This is due to an impressive portfolio of drugs for Urology.
New medicines for use in Urology are currently under evaluation through a major R&D programme. By focusing our resources and expertise in the areas of Urology that still have unmet medical needs, Astellas leads the way in developing pioneering treatments for conditions such as Benign Prostatic Hyperplasia (BPH), Prostate Cancer and Overactive Bladder (OAB), offering hope to patients.
Through our commitment to continuing research, support and understanding, we are working to identify and develop innovative solutions to the current challenges in Urology.
Learn more about our therapy areas:
Innovative therapies in preventing organ rejection after transplantation
World-leading approach in R&D to satisfy unmet patient needs in urological conditions
Our commitment is to developing first-in-class and best-in-class therapies
Addressing the complex challenges of serious fungal and bacterial infections
Pioneering treatments that effectively manage chronic pain